vs
EXELIXIS, INC.（EXEL）与Krystal Biotech, Inc.（KRYS）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是Krystal Biotech, Inc.的5.6倍（$598.7M vs $107.1M）。Krystal Biotech, Inc.净利率更高（48.0% vs 40.8%，领先7.1%）。Krystal Biotech, Inc.同比增速更快（17.5% vs 5.6%）。EXELIXIS, INC.自由现金流更多（$332.4M vs $75.4M）。过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs 18.7%）
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
EXEL vs KRYS — 直观对比
营收规模更大
EXEL
是对方的5.6倍
$107.1M
营收增速更快
KRYS
高出11.9%
5.6%
净利率更高
KRYS
高出7.1%
40.8%
自由现金流更多
EXEL
多$257.0M
$75.4M
两年增速更快
KRYS
近两年复合增速
18.7%
损益表 — Q4 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $598.7M | $107.1M |
| 净利润 | $244.5M | $51.4M |
| 毛利率 | 95.6% | — |
| 营业利润率 | 39.3% | 41.5% |
| 净利率 | 40.8% | 48.0% |
| 营收同比 | 5.6% | 17.5% |
| 净利润同比 | 74.8% | 13.0% |
| 每股收益（稀释后） | $0.89 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXELKRYS
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $107.1M | ||
| Q3 25 | $568.3M | $97.8M | ||
| Q2 25 | $555.4M | $96.0M | ||
| Q1 25 | $566.8M | $88.2M | ||
| Q4 24 | — | $91.1M | ||
| Q3 24 | $539.5M | $83.8M | ||
| Q2 24 | $637.2M | $70.3M |
净利润EXELKRYS
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $51.4M | ||
| Q3 25 | $184.8M | $79.4M | ||
| Q2 25 | $159.6M | $38.3M | ||
| Q1 25 | $139.9M | $35.7M | ||
| Q4 24 | — | $45.5M | ||
| Q3 24 | $118.0M | $27.2M | ||
| Q2 24 | $226.1M | $15.6M |
毛利率EXELKRYS
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
营业利润率EXELKRYS
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 41.5% | ||
| Q3 25 | 37.6% | 42.3% | ||
| Q2 25 | 33.6% | 40.9% | ||
| Q1 25 | 28.8% | 41.0% | ||
| Q4 24 | — | 45.4% | ||
| Q3 24 | 25.2% | 26.8% | ||
| Q2 24 | 43.3% | 12.2% |
净利率EXELKRYS
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 48.0% | ||
| Q3 25 | 32.5% | 81.2% | ||
| Q2 25 | 28.7% | 39.9% | ||
| Q1 25 | 24.7% | 40.5% | ||
| Q4 24 | — | 49.9% | ||
| Q3 24 | 21.9% | 32.4% | ||
| Q2 24 | 35.5% | 22.2% |
每股收益（稀释后）EXELKRYS
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.69 | ||
| Q3 25 | $0.65 | $2.66 | ||
| Q2 25 | $0.55 | $1.29 | ||
| Q1 25 | $0.47 | $1.20 | ||
| Q4 24 | — | $1.53 | ||
| Q3 24 | $0.40 | $0.91 | ||
| Q2 24 | $0.77 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $496.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $1.2B |
| 总资产 | $2.8B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXELKRYS
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $496.3M | ||
| Q3 25 | $791.1M | $392.6M | ||
| Q2 25 | $1.0B | $353.8M | ||
| Q1 25 | $1.1B | $308.8M | ||
| Q4 24 | — | $344.9M | ||
| Q3 24 | $1.2B | $374.0M | ||
| Q2 24 | $1.0B | $345.8M |
股东权益EXELKRYS
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $2.1B | $1.0B | ||
| Q1 25 | $2.2B | $984.7M | ||
| Q4 24 | — | $946.4M | ||
| Q3 24 | $2.3B | $885.8M | ||
| Q2 24 | $2.1B | $838.9M |
总资产EXELKRYS
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $1.3B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.8B | $1.1B | ||
| Q1 25 | $2.9B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $3.0B | $982.3M | ||
| Q2 24 | $2.8B | $917.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $333.5M | $77.5M |
| 自由现金流经营现金流 - 资本支出 | $332.4M | $75.4M |
| 自由现金流率自由现金流/营收 | 55.5% | 70.4% |
| 资本支出强度资本支出/营收 | 0.2% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.36× | 1.51× |
| 过去12个月自由现金流最近4个季度 | $875.8M | $188.9M |
8季度趋势，按日历期对齐
经营现金流EXELKRYS
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $77.5M | ||
| Q3 25 | $49.0M | $39.7M | ||
| Q2 25 | $211.4M | $52.7M | ||
| Q1 25 | $240.3M | $31.0M | ||
| Q4 24 | — | $52.8M | ||
| Q3 24 | $271.3M | $58.9M | ||
| Q2 24 | $119.5M | $-4.2M |
自由现金流EXELKRYS
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $75.4M | ||
| Q3 25 | $46.2M | $38.0M | ||
| Q2 25 | $208.5M | $50.8M | ||
| Q1 25 | $236.3M | $24.8M | ||
| Q4 24 | — | $52.0M | ||
| Q3 24 | $263.1M | $57.8M | ||
| Q2 24 | $113.0M | $-5.3M |
自由现金流率EXELKRYS
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 70.4% | ||
| Q3 25 | 8.1% | 38.8% | ||
| Q2 25 | 37.5% | 52.9% | ||
| Q1 25 | 41.7% | 28.1% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | 48.8% | 69.0% | ||
| Q2 24 | 17.7% | -7.5% |
资本支出强度EXELKRYS
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.0% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.5% | 2.0% | ||
| Q1 25 | 0.7% | 7.0% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 1.0% | 1.6% |
现金转化率EXELKRYS
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.51× | ||
| Q3 25 | 0.27× | 0.50× | ||
| Q2 25 | 1.32× | 1.38× | ||
| Q1 25 | 1.72× | 0.87× | ||
| Q4 24 | — | 1.16× | ||
| Q3 24 | 2.30× | 2.17× | ||
| Q2 24 | 0.53× | -0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
